10-Year Cardiac Risk Calculator

Why cholesterol sits at the center of cardiac risk

Cholesterol is the input on this page you can change on purpose, and the evidence that changing it changes outcomes is among the strongest in medicine. The Cholesterol Treatment Trialists collaboration pooled the major statin trials and found that each 39 mg/dL drop in LDL cholesterol, which is 1.0 mmol/L, cut major vascular events by about 22% a year. Bigger drops cut more.

The 2013 pooled cohort equations behind this calculator use total cholesterol and HDL rather than LDL, because those two values were measured the same way across the cohorts that trained the model. LDL still matters; it enters the equation indirectly, as the largest part of your total. Non-HDL cholesterol, which is total minus HDL, captures every cholesterol-carrying particle in one number, and many cardiologists prefer it for that reason.

That distinction matters when you read your result. The calculator is not asking what your LDL is. It is asking what your total and HDL are today, because those are the two numbers the model was trained on. The American Heart Association cholesterol guide explains where each number on the panel comes from.

Reading a lipid panel without the jargon

A standard US panel reports four or five values in mg/dL. Here is what each one contributes to the picture.

Common reference points: an LDL under 100 mg/dL is the usual prevention target, 160 to 189 is called high, and 190 or above is treated as a diagnosis in its own right. An HDL under 40 for men or under 50 for women counts as low. Triglycerides above 150 point to the metabolic cluster that travels with high blood pressure and high blood sugar.

One number on the report is easy to overread: the total to HDL ratio printed by some labs. It is a decent shorthand, but the equation already weighs both numbers separately and more precisely than any ratio can.

Worked example: one man, four cholesterol numbers

Take a 60-year-old man with HDL 38, systolic pressure 135, no blood pressure medicine, no smoking and no diabetes. His score moves with his total cholesterol like this.

Going from 260 to 180 removes about 40 events per 1,000 men over the decade. The same man with an HDL of 50 instead of 38, holding everything else at a total of 260, scores 11.9% instead of 14.4%. The HDL move is worth about two and a half points on its own, and the two stack: at a total of 180 with an HDL of 50 his score falls to about 8.6%.

That last figure is the useful one. Nothing about his age, blood pressure or smoking changed. Two lipid numbers moved, and his risk fell by 40%, from one event per seven men to one per twelve.

What lowers the number, and by how much

The table gathers the levers with the best evidence, in rough order of how far they move a score like the one above.

None of these rows is a promise. They are averages from trials of thousands of people, and individual responses to the same statin dose can differ by a factor of two. What the table does show is the size of each lever relative to the others, which is what a treatment decision needs.

Relative and absolute: what a 30% drop is worth

Statin benefits are usually reported as relative numbers, 30% or 50% fewer events, and those percentages are honest. What they mean for one person depends on where that person starts.

Our 60-year-old at 14.4% is the case to watch. A 30% relative drop lands him near 10.1%, which is 43 fewer events per 1,000 men like him over ten years. For a 45-year-old woman at 0.6%, the same 30% relative drop is 0.18 points, and it is still worth having, because over 30 years the gap compounds. Relative risk reduction travels with you; absolute benefit is what you feel.

This is why the same pill is an easy yes for the 41.6% patient and a genuine judgment call for the 5% patient, even though both get the same relative protection from it. The US Preventive Services Task Force statin recommendation makes the same point in guideline language: the decision belongs to the person with the higher absolute risk.

When cholesterol medicine is worth the conversation

The 2018 cholesterol guideline sorts people into four statin benefit groups, and the score from this page drives the last one.

• Anyone with clinical ASCVD: a high-intensity statin, no further calculation.
• LDL of 190 mg/dL or higher: treat the number, no score needed.
• Diabetes at ages 40 to 75: moderate-intensity statin, with intensity raised when other risks stack up.
• Ages 40 to 75 with LDL between 70 and 189 and a 10-year score of 7.5% or higher: a statin discussion, informed by risk enhancers and, when the call is close, a coronary calcium scan.

The scan earns its own sentence. A calcium score of zero moves roughly half of intermediate-risk patients into the low group and lets a statin wait. A score above 100 settles the argument in the other direction. It is the tiebreaker for exactly the 5% to 15% zone where the calculator alone cannot decide.

Statin intensity is simpler than the brand names suggest. High intensity means atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg, and it lowers LDL by half or more. Moderate intensity means atorvastatin 10 to 20 mg, rosuvastatin 5 to 10 mg, or simvastatin 20 to 40 mg, and it lowers LDL by 30% to 49%.

A 12-week plan that fits real life

Numbers on a page change nothing until they turn into a routine. This sequence is built around what can be measured.

• Weeks 1 and 2: get the baseline. One lipid panel, a week of home blood pressures, and an honest smoking answer. Without a baseline, the next panel proves nothing.
• Weeks 3 to 6: pick one diet change and keep it. The evidence favors swapping saturated fat for unsaturated fat: butter out, olive oil in, fish twice a week, a handful of nuts most days. Expect 10% to 15% off LDL, more if you go the full portfolio route.
• Weeks 5 to 12: build to 150 minutes of moderate movement a week, spread over at least three days. This is the row of the plan that moves blood pressure, the second lever inside the equation.
• Week 12: repeat the panel. Cholesterol responds to diet within about four weeks, so a 12-week recheck shows the trend, and if a statin entered the picture, whether the dose is doing its job.

Bring the two panels to the appointment side by side. A number that moved, even modestly, turns the statin conversation from abstract to concrete, and it tells your doctor whether the plan is working before anything stronger gets added.